PRESS RELEASES

Date Title View
Toggle Summary Chimerix names George Painter, PhD, Chairman of the Board & CSO; appoints Kenneth Moch, President & CEO
Chimerix names George Painter, PhD, Chairman of the Board & CSO; appoints Kenneth Moch, President & CEO RESEARCH TRIANGLE PARK, NC, May 4, 2010 – Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that Kenneth I.
View HTML
Toggle Summary Chimerix to Present at Future Leaders in the Biotech Industry Conference
Chimerix to Present at Future Leaders in the Biotech Industry Conference Research Triangle Park, NC, March 29, 2010 – Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, announced today that Kenneth I.
View HTML
Toggle Summary Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
- New Broad-Spectrum Antiviral Agent to Be Evaluated for Preventative and Therapeutic Activity
View HTML
Toggle Summary Chimerix CEO George Painter, Ph.D., to Speak at Institute of Medicine Workshop
- CMX001 data will also be presented in a poster session
View HTML
Toggle Summary Chimerix’s Antiviral CMX001 Abstract Selected for an Oral Presentation at EBMT's Annual Meeting
- CMX001 data will also be presented in a poster session
View HTML
Toggle Summary Chimerix to Present at Two Upcoming Investor Conferences
Chimerix to Present at Two Upcoming Investor Conferences Chimerix to Present at Two Upcoming Investor Conferences RESEARCH TRIANGLE PARK, NC, November 12, 2009 – Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases,
View HTML
Toggle Summary Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
View HTML
Toggle Summary Chimerix Raises $16.1 Million in Series E Financing
- CMX001 data will also be presented in a poster session
View HTML
Toggle Summary Chimerix’s Antiviral CMX001 Abstract Selected for an Oral Presentation at EBMT's Annual Meeting
- CMX001 data will also be presented in a poster session
View HTML
Toggle Summary Chimerix Joins International Network of Organizations to Cure Malaria
Chimerix Joins International Network of Organizations to Cure Malaria Chimerix Joins International Network of Organizations to Cure Malaria RESEARCH TRIANGLE PARK, NC, April 2, 2009 - Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that
View HTML